Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
American Journal of Clinical Dermatology
Erschienen in: American Journal of Clinical Dermatology 1/2017

01.02.2017 | Review Article

Paraneoplastic Pemphigus and Autoimmune Blistering Diseases Associated with Neoplasm: Characteristics, Diagnosis, Associated Neoplasms, Proposed Pathogenesis, Treatment

verfasst von: Saritha Kartan, Vivian Y. Shi, Ashley K. Clark, Lawrence S. Chan

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Autoimmune paraneoplastic and neoplasm-associated skin syndromes are characterized by autoimmune-mediated cutaneous lesions in the presence of a neoplasm. The identification of these syndromes provides information about the underlying tumor, systemic symptoms, and debilitating complications. The recognition of these syndromes is particularly helpful in cases of skin lesions presenting as the first sign of the malignancy, and the underlying malignancy can be treated in a timely manner. Autoimmune paraneoplastic and neoplasm-associated bullous skin syndromes are characterized by blister formation due to an autoimmune response to components of the epidermis or basement membrane in the context of a neoplasm. The clinical manifestations, histopathology and immunopathology findings, target antigens, associated neoplasm, current diagnostic criteria, current understanding of pathogenesis, and treatment options for a selection of four diseases are reviewed. Paraneoplastic pemphigus manifests with clinically distinct painful mucosal erosions and polymorphic cutaneous lesions, and is often associated with lymphoproliferative neoplasm. In contrast, bullous pemphigoid associated with neoplasm presents with large tense subepidermal bullae of the skin, and mild mucosal involvement, but without unique clinical features. Mucous membrane pemphigoid associated with neoplasm is a disorder of chronic subepithelial blisters that evolve into erosions and ulcerations that heal with scarring, and involves stratified squamous mucosal surfaces. Linear IgA dermatosis associated with neoplasm is characterized by annularly grouped pruritic papules, vesicles, and bullae along the extensor surfaces of elbows, knees, and buttocks. Physicians should be aware that these autoimmune paraneoplastic and neoplasm-associated syndromes can manifest distinct or similar clinical features as compared with the non-neoplastic counterparts.
Literatur
1.
Anhalt GJ, Kim SC, Stanley JR, et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med. 1990;323(25):1729–35.PubMedCrossRef
2.
Helm TN, Camisa C, Valenzuela R, Allen CM. Paraneoplastic pemphigus. A distinct autoimmune vesiculobullous disorder associated with neoplasia. Oral Surg Oral Med Oral Pathol. 1993;75(2):209–13.PubMedCrossRef
3.
Hong WJ, Lee SE, Chang SE, Hashimoto T, Kim SC. Paraneoplastic pemphigus associated with metastatic lymphoepithelioma-like carcinoma originating from the thyroid gland. Br J Dermatol. 2015;172(3):831–4.PubMedCrossRef
4.
Wang YZ, Gao ZY, Lei FM, Zhang JX, Gu J. A case report on paraneoplastic pemphigus associated colonic carcinoma. Chin Med J (Engl). 2016;129(12):1501–2.PubMedPubMedCentralCrossRef
5.
Garza-Chapa JI, Ocampo-Garza J, Vázquez-Herrera NE, et al. Paraneoplastic pemphigus associated with primary pulmonar follicular dendritic cell sarcoma showing good response to treatment. J Eur Acad Dermatol Venereol. 2016;30(3):465–7.PubMedCrossRef
6.
Chow SC, Yeung EC, Ng CS, et al. Mediastinal follicular dendritic cell sarcoma with paraneoplastic pemphigus. Asian Cardiovasc Thorac Ann. 2015;23(6):732–4.PubMedCrossRef
7.
Prakasan AM, Prabhu AJ, Velarasan K, Backianathan S, Ram TS. Paraneoplastic pemphigus associated with follicular dendritic cell tumor in the mediastinum. Case Rep Dermatol Med. 2016;2016:6901539.PubMedPubMedCentral
8.
Dinesha, Padyana M, Nayak K, Nirupama M, Pai DS. Castleman’s disease with paraneoplastic pemphigus. Indian J Dermatol. 2014;59(4):421.
9.
10.
11.
Mahmood T, Horner M, Menter A. Polymorphic blistering eruption and stomatitis in a patient with non-Hodgkin lymphoma. JAMA Dermatol. 2015;151(4):439–40.PubMedCrossRef
12.
Kumar S, Bishnoi K, Murugavaithianathan P, Panwar VK. Castleman’s disease presenting as localized abdominal mass and paraneoplastic pemphigus. J Clin Imaging Sci. 2016;6:6.PubMedPubMedCentralCrossRef
13.
Ghandi N, Ghanadan A, Azizian MR, et al. Paraneoplastic pemphigus associated with inflammatory myofibroblastic tumour of the mediastinum: a favourable response to treatment and review of the literature. Australas J Dermatol. 2015;56(2):120–3.PubMedCrossRef
14.
Su Z, Liu G, Liu J, et al. Paraneoplastic pemphigus associated with follicular dendritic cell sarcoma: report of a case and review of literature. Int J Clin Exp Pathol. 2015;8(10):11983–94.PubMedPubMedCentral
15.
Nguyen VT, Ndoye A, Bassler KD, et al. Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome: a reappraisal of paraneoplastic pemphigus. Arch Dermatol. 2001;137(2):193–206.PubMed
16.
Choi Y, Nam KH, Lee JB, et al. Retrospective analysis of 12 Korean patients with paraneoplastic pemphigus. J Dermatol. 2012;39(12):973–81.PubMedCrossRef
17.
Kelly S, Schifter M, Fulcher DA, Lin MW. Paraneoplastic pemphigus: two cases of intra-abdominal malignancy presenting solely as treatment refractory oral ulceration. J Dermatol. 2015;42(3):300–4.PubMedCrossRef
18.
Wang M, Wang X, Chen T, et al. Erosive oral lichen planus as a sign of paraneoplastic pemphigus. J Dermatol. 2016;43(8):983.PubMedCrossRef
19.
Choh NA, Qayoom S, Shaheen F, et al. Retroperitoneal Castlemans disease associated with paraneoplastic pemphigus. Hematol Oncol Stem Cell Ther. 2014;7(2):93–6.PubMedCrossRef
20.
Meyers SJ, Varley GA, Meisler DM, Camisa C, Wander AH. Conjunctival involvement in paraneoplastic pemphigus. Am J Ophthalmol. 1992;114(5):621–4.PubMedCrossRef
21.
Laforest C, Huilgol SC, Casson R, Selva D, Leibovitch I. Autoimmune bullous diseases: ocular manifestations and management. Drugs. 2005;65(13):1767–79.PubMedCrossRef
22.
Ahuero AE, Jakobiec FA, Bhat P, Ciralsky JB, Papaliodis GN. Paraneoplastic conjunctival cicatrization: two different pathogenic types. Ophthalmology. 2010;117(4):659–64.PubMedCrossRef
23.
Gong H, Zhou S, Hu Y, et al. Recurrent corneal melting in the paraneoplastic pemphigus associated with Castleman’s disease. BMC Ophthalmol. 2016;16:106.PubMedPubMedCentralCrossRef
24.
Broussard KC, Leung TG, Moradi A, Thorne JE, Fine JD. Autoimmune bullous diseases with skin and eye involvement: cicatricial pemphigoid, pemphigus vulgaris, and pemphigus paraneoplastica. Clin Dermatol. 2016;34(2):205–13.PubMedCrossRef
25.
Wang J, Zhu X, Li R, et al. Paraneoplastic pemphigus associated with Castleman tumor: a commonly reported subtype of paraneoplastic pemphigus in China. Arch Dermatol. 2005;141(10):1285–93.PubMedCrossRef
26.
Bowen GM, Peters NT, Fivenson DP, et al. Lichenoid dermatitis in paraneoplastic pemphigus: a pathogenic trigger of epitope spreading? Arch Dermatol. 2000;136(5):652–6.PubMedCrossRef
27.
Coelho S, Reis JP, Tellechea O, Figueiredo A, Black M. Paraneoplastic pemphigus with clinical features of lichen planus associated with low-grade B cell lymphoma. Int J Dermatol. 2005;44(5):366–71.PubMedCrossRef
28.
Hsiao CJ, Hsu MM, Lee JY, Chen WC, Hsieh WC. Paraneoplastic pemphigus in association with a retroperitoneal Castleman’s disease presenting with a lichen planus pemphigoides-like eruption. A case report and review of literature. Br J Dermatol. 2001;144(2):372–6.PubMedCrossRef
29.
Jansen T, Plewig G, Anhalt GJ. Paraneoplastic pemphigus with clinical features of erosive lichen planus associated with Castleman’s tumor. Dermatology. 1995;190(3):245–50.PubMedCrossRef
30.
Passeron T, Bahadoran P, Lacour JP, et al. Paraneoplastic pemphigus presenting as erosive lichen planus. Br J Dermatol. 1999;140(3):552–3.PubMedCrossRef
31.
Stevens SR, Griffiths CE, Anhalt GJ, Cooper KD. Paraneoplastic pemphigus presenting as a lichen planus pemphigoides-like eruption. Arch Dermatol. 1993;129(7):866–9.PubMedCrossRef
32.
Tey HL, Tang MB. A case of paraneoplastic pemphigus associated with Castleman’s disease presenting as erosive lichen planus. Clin Exp Dermatol. 2009;34(8):e754–6.PubMedCrossRef
33.
Yokokura H, Demitsu T, Kakurai M, et al. Paraneoplastic pemphigus mimicking erosive mucosal lichen planus associated with primary hepatocellular carcinoma. J Dermatol. 2006;33(12):842–5.PubMedCrossRef
34.
Frew JW, Murrell DF. Paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome): clinical presentations and pathogenesis. Dermatol Clin. 2011;29(3):419–25.PubMedCrossRef
35.
Hayanga AJ, Lee TM, Pannucci CJ, et al. Paraneoplastic pemphigus in a burn intensive care unit: case report and review of the literature. J Burn Care Res. 2010;31(5):826–9.PubMedPubMedCentralCrossRef
36.
Mahler V, Antoni C, Anhalt GJ, et al. Graft-versus-host-like mucocutaneous eruptions with serological features of paraneoplastic pemphigus and systemic lupus erythematosus in a patient with non-Hodgkin’s lymphoma. Dermatology. 1998;197(1):78–83.PubMedCrossRef
37.
Reich K, Brinck U, Letschert M, et al. Graft-versus-host disease-like immunophenotype and apoptotic keratinocyte death in paraneoplastic pemphigus. Br J Dermatol. 1999;141(4):739–46.PubMedCrossRef
38.
Hasegawa Y, Shimokata K, Ichiyama S, Saito H. Constrictive bronchiolitis obliterans and paraneoplastic pemphigus. Eur Respir J. 1999;13(4):934–7.PubMedCrossRef
39.
Maldonado F, Pittelkow MR, Ryu JH. Constrictive bronchiolitis associated with paraneoplastic autoimmune multi-organ syndrome. Respirology. 2009;14(1):129–33.PubMedCrossRef
40.
Nousari HC, Deterding R, Wojtczack H, et al. The mechanism of respiratory failure in paraneoplastic pemphigus. N Engl J Med. 1999;340(18):1406–10.PubMedCrossRef
41.
Chin AC, Stich D, White FV, Radhakrishnan J, Holterman MJ. Paraneoplastic pemphigus and bronchiolitis obliterans associated with a mediastinal mass: a rare case of Castleman’s disease with respiratory failure requiring lung transplantation. J Pediatr Surg. 2001;36(12):E22.PubMed
42.
Kanaoka M, Matsukura S, Ishikawa H, et al. Paraneoplastic pemphigus associated with fatal bronchiolitis obliterans and appearance of anti-BP180 antibodies in the late stage of the disease. J Dermatol. 2014;41(7):628–30.PubMedCrossRef
43.
Healy WJ, Peters S, Nana-Sinkam SP. A middle-aged man presenting with unexplained mucosal erosions and progressive dyspnoea. BMJ Case Rep. 2015;2015:1–3.
44.
Kobayashi K, Ohshima N, Shimada M, et al. An autopsy case of unicentric Castleman’s disease associated with bronchiolitis obliterans. Respirol Case Rep. 2014;2(3):105–107.
45.
Leger S, Picard D, Ingen-Housz-Oro S, Arnault JP, et al. Prognostic factors of paraneoplastic pemphigus. Arch Dermatol. 2012;148(10):1165–72.PubMedCrossRef
46.
Dong Y, Wang M, Nong L, Wang L, Cen X, Liu W, Zhu S, Sun Y, Liang Z, Li Y, Ou J, Qiu Z, Ren H. Clinical and laboratory characterization of 114 cases of Castleman disease patients from a single centre: paraneoplastic pemphigus is an unfavourable prognostic factor. Br J Haematol. 2015;169(6):834–42.PubMedCrossRef
47.
Horn TD, Anhalt GJ. Histologic features of paraneoplastic pemphigus. Arch Dermatol. 1992;128(8):1091–5.PubMedCrossRef
48.
Porro AM, Caetano Lde V, Maehara Lde S, Enokihara MM. Non-classical forms of pemphigus: pemphigus herpetiformis, IgA pemphigus, paraneoplastic pemphigus and IgG/IgA pemphigus. An Bras Dermatol. 2014;89(1):96–106.PubMedPubMedCentralCrossRef
49.
50.
Mutasim DF, Pelc NJ, Anhalt GJ. Paraneoplastic pemphigus, pemphigus vulgaris, and pemphigus foliaceus. Clin Dermatol. 1993;11(1):113–7.PubMedCrossRef
51.
Liu AY, Valenzuela R, Helm TN, Camisa C, Melton AL, Bergfeld WF. Indirect immunofluorescence on rat bladder transitional epithelium: a test with high specificity for paraneoplastic pemphigus. J Am Acad Dermatol. 1993;28(5 Pt 1):696–9.PubMedCrossRef
52.
Poot AM, Siland J, Jonkman MF, Pas HH, Diercks GF. Direct and indirect immunofluorescence staining patterns in the diagnosis of paraneoplastic pemphigus. Br J Dermatol. 2016;174(4):912–5.PubMedCrossRef
53.
Kelly S, Culican S, Silvestrini RA, et al. Comparative study of five serological assays for diagnosis of paraneoplastic pemphigus. Pathology. 2015;47(1):58–61.PubMedCrossRef
54.
Ishii N, Teye K, Fukuda S, et al. Anti-desmocollin autoantibodies in nonclassical pemphigus. Br J Dermatol. 2015;173(1):59–68.PubMedCrossRef
55.
Oursler JR, Labib RS, Ariss-Abdo L, Burke T, O’Keefe EJ, Anhalt GJ. Human autoantibodies against desmoplakins in paraneoplastic pemphigus. J Clin Invest. 1992;89(6):1775–82.PubMedPubMedCentralCrossRef
56.
Kiyokawa C, Ruhrberg C, Nie Z, et al. Envoplakin and periplakin are components of the paraneoplastic pemphigus antigen complex. J Invest Dermatol. 1998;111(6):1236–8.PubMedCrossRef
57.
Sonnenberg A, Liem RK. Plakins in development and disease. Exp Cell Res. 2007;313(10):2189–203.PubMedCrossRef
58.
Jefferson JJ, Leung CL, Liem RK. Plakins: goliaths that link cell junctions and the cytoskeleton. Nat Rev Mol Cell Biol. 2004;5(7):542–53.PubMedCrossRef
59.
Gallo E, Garcia-Martin P, Fraga J, et al. Paraneoplastic pemphigus with eosinophilic spongiosis and autoantibodies against desmocollins 2 and 3. Clin Exp Dermatol. 2014;39(3):323–6.PubMedCrossRef
60.
Otsuka Y, Ueno T, Yamase A, et al. Case of paraneoplastic pemphigus with immunoglobulin (Ig)G and IgA antibodies to various antigens. J Dermatol. 2016;43(8):944–6.PubMedCrossRef
61.
Schepens I, Jaunin F, Begre N, et al. The protease inhibitor alpha-2-macroglobulin-like-1 is the p170 antigen recognized by paraneoplastic pemphigus autoantibodies in human. PLoS One. 2010;5(8):e12250.PubMedPubMedCentralCrossRef
62.
Numata S, Teye K, Tsuruta D, et al. Anti-α-2-macroglobulin-like-1 autoantibodies are detected frequently and may be pathogenic in paraneoplastic pemphigus. J Invest Dermatol. 2013;133(7):1785–93.PubMedCrossRef
63.
Poot AM, Diercks GF, Kramer D, et al. Laboratory diagnosis of paraneoplastic pemphigus. Br J Dermatol. 2013;169(5):1016–24.PubMedCrossRef
64.
Hashimoto T, Amagai M, Watanabe K, et al. Characterization of paraneoplastic pemphigus autoantigens by immunoblot analysis. J Invest Dermatol. 1995;104(5):829–34.PubMedCrossRef
65.
Mahoney MG, Aho S, Uitto J, Stanley JR. The members of the plakin family of proteins recognized by paraneoplastic pemphigus antibodies include periplakin. J Invest Dermatol. 1998;111(2):308–13.PubMedCrossRef
66.
Borradori L, Trueb RM, Jaunin F, Limat A, Favre B, Saurat JH. Autoantibodies from a patient with paraneoplastic pemphigus bind periplakin, a novel member of the plakin family. J Invest Dermatol. 1998;111(2):338–40.PubMedCrossRef
67.
Ahn JH, Lee MG, Kim SC, Lee TH. A monoclonal antibody against the paraneoplastic pemphigus (PNP) antigen, envoplakin: cDNA sequences encoding the variable regions of heavy and light chains. Mol Cells. 2004;18(2):237–41.PubMed
68.
Kim SC, Kwon YD, Lee IJ, Chang SN, Lee TG. cDNA cloning of the 210-kDa paraneoplastic pemphigus antigen reveals that envoplakin is a component of the antigen complex. J Invest Dermatol. 1997;109(3):365–9.PubMedCrossRef
69.
Nagata Y, Karashima T, Watt FM, Salmhofer W, Kanzaki T, Hashimoto T. Paraneoplastic pemphigus sera react strongly with multiple epitopes on the various regions of envoplakin and periplakin, except for the c-terminal homologous domain of periplakin. J Invest Dermatol. 2001;116(4):556–63.PubMedCrossRef
70.
Proby C, Fujii Y, Owaribe K, Nishikawa T, Amagai M. Human autoantibodies against HD1/plectin in paraneoplastic pemphigus. J Invest Dermatol. 1999;112(2):153–6.PubMedCrossRef
71.
Tsuchisaka A, Numata S, Teye K, et al. Epiplakin is a paraneoplastic pemphigus autoantigen and related to bronchiolitis obliterans in Japanese patients. J Invest Dermatol. 2016;136(2):399–408.PubMedCrossRef
72.
Amagai M, Nishikawa T, Nousari HC, Anhalt GJ, Hashimoto T. Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice. J Clin Invest. 1998;102(4):775–82.PubMedPubMedCentralCrossRef
73.
Probst C, Schlumberger W, Stocker W, et al. Development of ELISA for the specific determination of autoantibodies against envoplakin and periplakin in paraneoplastic pemphigus. Clin Chim Acta. 2009;410(1–2):13–8.PubMedCrossRef
74.
Zhang B, Zheng R, Wang J, Bu D, Zhu X. Epitopes in the linker subdomain region of envoplakin recognized by autoantibodies in paraneoplastic pemphigus patients. J Invest Dermatol. 2006;126(4):832–40.PubMedCrossRef
75.
Li J, Bu DF, Huang YC, Zhu XJ. Role of autoantibodies against the linker subdomains of envoplakin and periplakin in the pathogenesis of paraneoplastic pemphigus. Chin Med J (Engl). 2009;122(5):486–95.PubMed
76.
Wang X, Chen T, Zhao J, et al. Extremities of the N-terminus of envoplakin and C-terminus of its linker subdomain are major epitopes of paraneoplastic pemphigus. J Dermatol Sci. 2016;84(1):24–9.PubMedCrossRef
77.
Wang R, Li J, Wang M, et al. Prevalence of myasthenia gravis and associated autoantibodies in paraneoplastic pemphigus and their correlations with symptoms and prognosis. Br J Dermatol. 2015;172(4):968–75.PubMedCrossRef
78.
Mouquet H, Drenovska K, Lartigue A, et al. Detection and characterization of anti-envoplakin linker autoantibodies in paraneoplastic pemphigus using specific bead-based assay. Clin Immunol. 2008;129(2):304–12.PubMedCrossRef
79.
Kaplan I, Hodak E, Ackerman L, Mimouni D, Anhalt GJ, Calderon S. Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal manifestations. Oral Oncol. 2004;40(6):553–62.PubMedCrossRef
80.
Ohzono A, Sogame R, Li X, et al. Clinical and immunological findings in 104 cases of paraneoplastic pemphigus. Br J Dermatol. 2015;173(6):1447–52.PubMedCrossRef
81.
Amber KT. Reply to: clinical and immunological findings in 104 cases of paraneoplastic pemphigus. Br J Dermatol. 2016;174(2):461.PubMedCrossRef
82.
Marathe K, Lu J, Morel KD. Bullous diseases: kids are not just little people. Clin Dermatol. 2015;33(6):644–56.PubMedCrossRef
83.
Kitagawa C, Nakajima K, Aoyama Y, et al. A typical case of paraneoplastic pemphigus without detection of malignancy: effectiveness of plasma exchange. Acta Derm Venereol. 2014;94(3):359–61.PubMedCrossRef
84.
Sprecher E. Paraneoplastic pemphigus: an entity still in search of an identity? Br J Dermatol. 2015;173(6):1363–4.PubMedCrossRef
85.
Czernik A, Camilleri M, Pittelkow MR, Grando SA. Paraneoplastic autoimmune multiorgan syndrome: 20 years after. Int J Dermatol. 2011;50(8):905–14.PubMedCrossRef
86.
Joly P, Richard C, Gilbert D, et al. Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol. 2000;43(4):619–26.PubMedCrossRef
87.
Cummins DL, Mimouni D, Tzu J, Owens N, Anhalt GJ, Meyerle JH. Lichenoid paraneoplastic pemphigus in the absence of detectable antibodies. J Am Acad Dermatol. 2007;56(1):153–9.PubMedCrossRef
88.
Meager A, Wadhwa M, Dilger P, et al. Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin Exp Immunol. 2003;132(1):128–36.PubMedPubMedCentralCrossRef
89.
Hashimoto T. Immunopathology of paraneoplastic pemphigus. Clin Dermatol. 2001;19(6):675–82.PubMedCrossRef
90.
Wang L, Bu D, Yang Y, Chen X, Zhu X. Castleman’s tumours and production of autoantibody in paraneoplastic pemphigus. Lancet. 2004;363(9408):525–31.PubMedCrossRef
91.
Hashimoto T. Production of numerous antibodies in paraneoplastic pemphigus. Br J Dermatol. 2015;172(4):844–60.CrossRef
92.
Maverakis E, Goodarzi H, Wehrli LN, Ono Y, Garcia MS. The etiology of paraneoplastic autoimmunity. Clin Rev Allergy Immunol. 2012;42(2):135–44.
93.
Thompson ED, Enriquez HL, Fu YX, Engelhard VH. Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J Exp Med. 2010;207(8):1791–804.PubMedPubMedCentralCrossRef
94.
95.
Chan LS. Epitope spreading in paraneoplastic pemphigus: autoimmune induction in antibody-mediated blistering skin diseases. Arch Dermatol. 2000;136(5):663–4.PubMedCrossRef
96.
Ohyama M, Amagai M, Hashimoto T, Nousari HC, Anhalt GJ, Nishikawa T. Clinical phenotype and anti-desmoglein autoantibody profile in paraneoplastic pemphigus. J Am Acad Dermatol. 2001;44(4):593–8.PubMedCrossRef
97.
Sanz-Bueno J, Cullen D, Zarco C, Vanaclocha F. Paraneoplastic autoimmune multiorgan syndrome (paraneoplastic pemphigus) with unusual manifestations and without detectable autoantibodies. Indian J Dermatol Venereol Leprol. 2014;80(4):328–30.PubMedCrossRef
98.
Nousari HC, Kimyai-Asadi A, Anhalt GJ. Elevated serum levels of interleukin-6 in paraneoplastic pemphigus. J Invest Dermatol. 1999;112:396–8.PubMedCrossRef
99.
Voorzanger N, Touitou R, Garcia E, et al. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin’s lymphoma cells and act as cooperative growth factors. Cancer Res. 1996;56:5499–505.PubMed
100.
Bonekamp D, Hruban RH, Fishman EK. The great mimickers: Castleman disease. Semin Ultrasound CT MR. 2014;35(3):263–71.PubMedCrossRef
101.
Billet SE, Grando SA, Pittelkow MR. Paraneoplastic autoimmune multiorgan syndrome: review of the literature and support for a cytotoxic role in pathogenesis. Autoimmunity. 2006;39(7):617–30.PubMedCrossRef
102.
103.
Tsuchisaka A, Kawano H, Yasukochi A, et al. Immunological and statistical studies of anti-BP180 antibodies in paraneoplastic pemphigus. J Invest Dermatol. 2014;134(8):2283–7.PubMedCrossRef
104.
Oh SJ, Lee SE, Hashimoto T, Kim SC. A case of paraneoplastic pemphigus associated with Castleman disease reacting with multiple autoantigens, including the p200 protein. Br J Dermatol. 2016;174(4):930–2.PubMedCrossRef
105.
Gill H, Trendell-Smith NJ, Loong F, Chan JC, Kwong YL. Paraneoplastic pemphigus due to natural-killer/T-cell lymphoma. Br J Haematol. 2011;154(2):160.PubMedCrossRef
106.
Hoffman MA, Qiao X, Anhalt GJ. CD8+ T lymphocytes in bronchiolitis obliterans, paraneoplastic pemphigus, and solitary Castleman’s disease. N Engl J Med. 2003;349(4):407–8.PubMedCrossRef
107.
Hata T, Nishimoto S, Nagao K, et al. Ectopic expression of epidermal antigens renders the lung a target organ in paraneoplastic pemphigus. J Immunol. 2013;191(1):83–90.PubMedCrossRef
108.
Frew JW, Murrell DF. Current management strategies in paraneoplastic pemphigus (paraneoplastic autoimmune multiorgansyndrome). Dermatol Clin. 2011;29(4):607–12.PubMedCrossRef
109.
Vezzoli P, Berti E, Marzano AV. Rationale and efficacy for the use of rituximab in paraneoplastic pemphigus. Expert Rev Clin Immunol. 2008;4(3):351–63.PubMedCrossRef
110.
Namba C, Tohyama M, Hanakawa Y, et al. Paraneoplastic pemphigus associated with fatal bronchiolitis obliterans and intractable mucosal erosions: treatment with cyclosporin in addition to steroid, rituximab and intravenous immunoglobulin. J Dermatol. 2016;43(4):419–22.PubMedCrossRef
111.
Hirano T, Higuchi Y, Yuki H, et al. Rituximab monotherapy and rituximab-containing chemotherapy were effective for paraneoplastic pemphigus accompanying follicular lymphoma, but not for subsequent bronchiolitis obliterans. J Clin Exp Hematop. 2015;55(2):83–8.PubMedCrossRef
112.
Fang Y, Zhao L, Yan F, Cui X, Xia Y, Duren A. A critical role of surgery in the treatment for paraneoplastic pemphigus caused by localized Castleman’s disease. Med Oncol. 2010;27(3):907–11.PubMedCrossRef
113.
Zhang J, Qiao QL, Chen XX, et al. Improved outcomes after complete resection of underlying tumors for patients with paraneoplastic pemphigus: a single-center experience of 22 cases. J Cancer Res Clin Oncol. 2011;137(2):229–34.PubMedCrossRef
114.
Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized antiinterleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106(8):2627–32.PubMedCrossRef
115.
Schadlow MB, Anhalt GJ, Sinha AA. Using rituximab (anti-CD20 antibody) in a patient with paraneoplastic pemphigus. J Drugs Dermatol. 2003;2(5):564–7.PubMed
116.
Aoi J, Makino K, Sakai K, et al. Case of paraneoplastic pemhpigus with follicular lymphoma treated with rituximab. J Dermatol. 2013;40(4):285–6.PubMedCrossRef
117.
Kanwar AJ, Vinay K, Varma S, et al. Anti-desmoglein antibody-negative paraneoplastic pemphigus successfully treated with rituximab. Int J Dermatol. 2015;54(5):576–9.PubMedCrossRef
118.
Wang L, Deng H, Mao M. Paraneoplastic pemphigus and myasthenia gravis, associated with inflammatory pseudotumor-like follicular dendritic cell sarcoma: response to rituximab. Clin Case Rep. 2016;4(8):797–9.PubMedPubMedCentralCrossRef
119.
Hwang YY, Chan JC, Trendell-Smith NJ, et al. Recalcitrant paraneoplastic pemphigus associated with follicular dendritic cell sarcoma: response to prolonged rituximab and ciclosporin therapy. Intern Med J. 2014;44(11):1145–6.PubMedCrossRef
120.
Bech R, Baumgartner-Nielsen J, Peterslund NA, Steiniche T, Deleuran M, d’Amore F. Alemtuzumab is effective against severe chronic lymphocytic leukaemia-associated paraneoplastic pemphigus. Br J Dermatol. 2013;169(2):469–72.PubMedCrossRef
121.
Ekbäck M, Uggla B. Paraneoplastic pemphigus associated with chronic lymphocytic leukaemia: treatment with alemtuzumab. Leuk Res. 2012;36(8):e190–1.PubMedCrossRef
122.
Lee SY, Kim JH, Cho DH. High-dose-rate intraluminal brachytherapy for paraneoplastic autoimmune multiorgan syndrome. Exp Ther Med. 2016;12(3):1435–9.PubMedPubMedCentral
123.
Chan LS (2016) Pemphigus vulgaris: scientific basis, clinical presentations, diagnostic methodology, and management strategies. Hauppauge, NY: Nova Science Publishers, Incorporated
124.
Balestri R, Magnano M, La Placa M, Patrizi A, Angileri L, Tengattini V, Bardazzi F. Malignancies in bullous pemphigoid: a controversial association. J Dermatol. 2016;43(2):125–33.PubMedCrossRef
125.
Jedlickova H, Hlubinka M, Pavlik T, Semradova V, Budinska E, Vlasin Z. Bullous pemphigoid and internal diseases—a case-control study. Eur J Dermatol. 2010;20(1):96–101.PubMed
126.
Kolanko E, Bickle K, Keehn C, Glass LF. Subepidermal blistering disorders: a clinical and histopathologic review. Semin Cutan Med Surg. 2004;23(1):10–8.PubMedCrossRef
127.
Bingham EA, Burrows D, Sandford JC. Prolonged pruritus and bullous pemphigoid. Clin Exp Dermatol. 1984;9(6):564–70.PubMedCrossRef
128.
Person JR, Rogers RS 3rd. Bullous and cicatricial pemphigoid. Clinical, histopathologic, and immunopathologic correlations. Mayo Clin Proc. 1977;52(1):54–66.PubMed
129.
Bickle K, Roark TR, Hsu S. Autoimmune bullous dermatoses: a review. Am Fam Physician. 2002;65(9):1861–70.PubMed
130.
Mutasim DF. Autoimmune bullous dermatoses in the elderly: diagnosis and management. Drugs Aging. 2003;20(9):663–81.PubMedCrossRef
131.
Gilmour E, Bhushan M, Griffiths CE. Figurate erythema with bullous pemphigoid: a true paraneoplastic phenomenon? Clin Exp Dermatol. 1999;24(6):446–8.PubMedCrossRef
132.
Hauschild A, Swensson O, Christophers E. Paraneoplastic bullous pemphigoid resembling erythema gyratum repens. Br J Dermatol. 1999;140(3):550–2.PubMedCrossRef
133.
Eustace S, Morrow G, O’Loughlin S, O’Connell D. The role of computed tomography and sonography in acute bullous pemphigoid. Ir J Med Sci. 1993;162(10):401–4.PubMedCrossRef
134.
Cakmak O, Seckin D, Ceken I, Yilmaz I, Akkuzu B, Ozluoglu L. Bullous pemphigoid associated with parotid carcinoma. Otolaryngol Head Neck Surg. 2002;127(4):354–6.PubMedCrossRef
135.
Umekoji A, Tsuruta D, Inoue T, Nishimori T, Ishii M. Bullous pemphigoid as a dermadrome associated with spindle cell carcinoma of the gallbladder. J Dermatol. 2010;37(3):251–4.PubMedCrossRef
136.
Ameen M, Pembroke AC, Black MM, Russell-Jones R. Eosinophilic spongiosis in association with bullous pemphigoid and chronic lymphocytic leukaemia. Br J Dermatol. 2000;143(2):421–4.PubMedCrossRef
137.
Karpouzis A, Vamvassakis E, Stavrianeas N, Koumantaki-Mathioudaki E, Karpouzi M, Vareltzides A. Ultrastructural immunocytochemistry of autoimmune bullous diseases. Australas J Dermatol. 2002;43(2):113–9.PubMedCrossRef
138.
Cotell S, Robinson ND, Chan LS. Autoimmune blistering skin diseases. Am J Emerg Med. 2000;18(3):288–99.PubMedCrossRef
139.
Delmonte S, Cozzani E, Drosera M, Parodi A, Rebora A. Rat bladder epithelium: a sensitive substrate for indirect immunofluorescence of bullous pemphigoid. Acta Derm Venereol. 2000;80(3):175–8.PubMedCrossRef
140.
Weigand DA, Clements MK. Direct immunofluorescence in bullous pemphigoid: effects of extent and location of lesions. J Am Acad Dermatol. 1989;20(3):437–40.PubMedCrossRef
141.
Cozzani E, Parodi A, Rebora A, et al. Bullous pemphigoid in Liguria: a 2-year survey. J Eur Acad Dermatol Venereol. 2001;15(4):317–9.PubMed
142.
Muramatsu T, Iida T, Tada H, et al. Bullous pemphigoid associated with internal malignancies: identification of 180-kDa antigen by western immunoblotting. Br J Dermatol. 1996;135(5):782–4.PubMedCrossRef
143.
Hodge L, Marsden RA, Black MM, Bhogal B, Corbett MF. Bullous pemphigoid: the frequency of mucosal involvement and concurrent malignancy related to indirect immunofluorescence findings. Br J Dermatol. 1981;105(1):65–9.PubMedCrossRef
144.
Venencie PY, Rogers RS 3rd, Schroeter AL. Bullous pemphigoid and malignancy: relationship to indirect immunofluorescent findings. Acta Derm Venereol. 1984;64(4):316–9.PubMed
145.
Mihályi L, Kiss M, Dobozy A, Kemény L, Husz S. Clinical relevance of autoantibodies in patients with autoimmune bullous dermatosis. Clin Dev Immunol. 2012;2012:369546.PubMedPubMedCentralCrossRef
146.
Groth S, Recke A, Vafia K, et al. Development of a simple enzyme-linked immunosorbent assay for the detection of autoantibodies in anti-p200 pemphigoid. Br J Dermatol. 2011;164(1):76–82.PubMedCrossRef
147.
Song HJ, Han SH, Hong WK, Lee HS, Shin JH, Choi GS. Paraneoplastic bullous pemphigoid: clinical disease activity correlated with enzyme-linked immunosorbent assay index for the NC16A domain of BP180. J Dermatol. 2009;36(1):66–8.PubMedCrossRef
148.
Lindelof B, Islam N, Eklund G, Arfors L. Pemphigoid and cancer. Arch Dermatol. 1990;126(1):66–8.PubMedCrossRef
149.
Ortiz LJ, Vazquez M, Sanchez JL. Bullous pemphigoid and malignancy. Bol Asoc Med P R. 1990;82(10):458–459.
150.
Cai SC, Allen JC, Lim YL, Tan SH, Tang MB. Association of bullous pemphigoid and malignant neoplasms. JAMA Dermatol. 2015;151(6):665–7.PubMedCrossRef
151.
Venning VA, Wojnarowska F. The association of bullous pemphigoid and malignant disease: a case control study. Br J Dermatol. 1990;123(4):439–45.PubMedCrossRef
152.
Schulze F, Neumann K, Recke A, Zillikens D, Linder R, Schmidt E. Malignancies in pemphigus and pemphigoid diseases. J Invest Dermatol. 2015;135(5):1445–7.PubMedCrossRef
153.
154.
Modiano P, Reichert S, Barbaud A, Bernard P, Weber M, Schmutz JL. Bullous pemphigoid in association with cutaneous lesions specific to a myelodysplastic syndrome. Br J Dermatol. 1997;136(3):402–5.PubMedCrossRef
155.
Egan CA, Florell SR, Zone JJ. Localized bullous pemphigoid in a patient with B-cell lymphoma. S Med J. 1999;92(12):1220–2.CrossRef
156.
Iuliano L, Micheletta F, Natoli S. Bullous pemphigoid: an unusual and insidious presentation of breast cancer. Clin Oncol (R Coll Radiol). 2003;15(8):505.PubMedCrossRef
157.
Gul U, Kilic A, Demirel O, Cakmak SK, Gonul M, Oksal A. Bullous pemphigoid associated with breast carcinoma. Eur J Dermatol. 2006;16(5):581–2.PubMed
158.
Bottoni U, Mauro FR, Cozzani E, et al. Bullous lesions in chronic lymphocytic leukaemia: pemphigoid or insect bites? Acta Derm Venereol. 2006;86(1):74–6.PubMed
159.
Bergler-Czop B, Lis-Swicty A, Brzezinska-Wcislo L, Podskarbi M. Bullous pemphigoid in the course of breast diseases: both breasts, neoplasmatic tumor; right breast, neoplasmatic tumor; and mastopathy–presentation of three cases in women aged 65 and older. J Am Geriatr Soc. 2009;57(4):754–6.PubMedCrossRef
160.
Patel M, Sinha AA, Gilbert E. Bullous pemphigoid associated with renal cell carcinoma and invasive squamous cell carcinoma. J Drugs Dermatol. 2012;11(2):234–8.PubMed
161.
Ng SS, Teo RY, Seah PP. A case of bullous pemphigoid in a patient with dual cancers, fortuitous or paraneoplastic? Ann Acad Med Singap. 2012;41(7):313–314.
162.
Kassim JM, Igali L, Levell NJ. A 14-year paraneoplastic rash: urticarial vasculitis and dermal binding bullous pemphigoid secondary to chronic lymphocytic leukaemia. Clin Exp Dermatol. 2015;40(4):391–4.PubMedCrossRef
163.
Venugopal V, Gnanaraj P, Fernandes SD, Narasimhan M, Karthikeyan S, Rahul S. Squamous cell carcinoma of penis with bullous pemphigoid masquerading as lymphogranuloma venereum. Indian J Sex Transm Dis. 2013;34(1):41–3.PubMedPubMedCentralCrossRef
164.
Das A, Das S, Das SK, Basuthakur S. A case of paraneoplastic bullous pemphigoid in association with squamous cell carcinoma of lung. J Postgrad Med. 2015;61(3):197–9.PubMedPubMedCentralCrossRef
165.
Maki N, Demitsu T, Umemoto N, Nagashima K, Nakamura T, Kakurai M, Nakamura S, Yamada T, Ishii N, Hashimoto T. Possible paraneoplastic syndrome case of bullous pemphigoid with immunoglobulin G anti-BP180 C-terminal domain antibodies associated with psoriasis and primary macroglobulinemia. J Dermatol. 2016;43(5):571–4.PubMedCrossRef
166.
Korekawa A, Kaneko T, Nakajima K, et al. Mycosis fungoides bullosa associated with bullous pemphigoid. Int J Dermatol. 2015;54(9):e366–8.PubMedCrossRef
167.
Stoica LE, Patrascu V, Dascalu RC, Ciurea ME. Bullous pemphigoid associated with psoriasis, breast cancer and Parkinson’s disease. Curr Health Sci J. 2014;40(1):62–6.PubMed
168.
Chang YT, Liu HN, Wong CK. Bullous pemphigoid–a report of 86 cases from Taiwan. Clin Exp Dermatol. 1996;21(1):20–2.PubMedCrossRef
169.
Morioka S, Sakuma M, Ogawa H. The incidence of internal malignancies in autoimmune blistering diseases: pemphigus and bullous pemphigoid in Japan. Dermatology. 1994;189(Suppl 1):82–4.PubMedCrossRef
170.
Ogawa H, Sakuma M, Morioka S, et al. The incidence of internal malignancies in pemphigus and bullous pemphigoid in Japan. J Dermatol Sci. 1995;9(2):136–41.PubMedCrossRef
171.
Ong E, Goldacre R, Hoang U, Sinclair R, Goldacre M. Associations between bullous pemphigoid and primary malignant cancers: an English national record linkage study, 1999–2011. Arch Dermatol Res. 2014;306(1):75–80.PubMedCrossRef
172.
Deguchi M, Tsunoda T, Tagami H. Resolution of bullous pemphigoid and improvement of vitiligo after successful treatment of squamous cell carcinoma of the skin. Clin Exp Dermatol. 1999;24(1):14–5.PubMedCrossRef
173.
Klein T, Rotterdam S, Noldus J, Hinkel A. Bullous pemphigoid is a rare paraneoplastic syndrome in patients with renal cell carcinoma. Scand J Urol Nephrol. 2009;43(4):334–6.PubMedCrossRef
174.
Noguchi K, Kawamura H, Ishizu H, Okada K. Dramatic resolution of bullous pemphigoid after surgery for gastric cancer: a case report. Int J Surg Case Rep. 2014;5(4):212–4.PubMedPubMedCentralCrossRef
175.
176.
Parimi LR, Chen M, Liu H, Zhang F. Bullous pemphigoid with malignant melanoma. Indian J Dermatol Venereol Leprol. 2015;81(6):625–6.PubMedCrossRef
177.
Rachadi H, Zemmez Y, Znati K, Ismaili N, Hassam B. External ear nodule revealing a disseminated Kaposi disease. Dermatol Online J. 2016;22(8).
178.
Wang T, Li C, Yang C, et al. Identification of human herpesvirus-8 in Kaposi’s sarcoma with bullous pemphigoid. Chin Med J (Engl). 2014;127(4):786–8.PubMed
179.
180.
Venning VA, Taylor CJ, Ting A, Wojnarowska F. HLA type in bullous pemphigoid, cicatricial pemphigoid and linear IgA disease. Clin Exp Dermatol. 1989;14(4):283–5.PubMedCrossRef
181.
Hamada T, Nagata Y, Tomita M, Salmhofer W, Hashimoto T. Bullous pemphigoid sera react specifically with various domains of BP230, most frequently with C-terminal domain, by immunoblot analyses using bacterial recombinant proteins covering the entire molecule. Exp Dermatol. 2001;10(4):256–63.PubMedCrossRef
182.
Yanagi T, Kato N, Yamane N, Osawa R. Bullous pemphigoid associated with dermatomyositis and colon carcinoma. Clin Exp Dermatol. 2007;32(3):291–4.PubMedCrossRef
183.
184.
Tukaj S, Zillikens D, Kasperkiewicz M. Heat shock protein 90: a pathophysiological factor and novel treatment target in autoimmune bullous skin diseases. Exp Dermatol. 2015;24(8):567–71.PubMedCrossRef
185.
Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346(5):321–7.PubMedCrossRef
186.
Lee JB, Fumimori T, Kurose K, Mori O, Hashimoto T. A case of bullous pemphigoid successfully treated by plasmapheresis: assessment of the change in titers of circulating antibodies by immunoblotting and enzyme-linked immunosorbent assay. J Dermatol. 2003;30(4):326–31.PubMedCrossRef
187.
Czernik A, Bystryn JC. Improvement of intravenous immunoglobulin therapy for bullous pemphigoid by adding immunosuppressive agents: marked improvement in depletion of circulating autoantibodies. Arch Dermatol. 2008;144(5):658–61.PubMed
188.
Schmidt E, Seitz CS, Benoit S, Brocker EB, Goebeler M. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol. 2007;156(2):352–6.PubMedCrossRef
189.
Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol. 2002;138(3):370–9.PubMedCrossRef
190.
Vassileva S, Drenovska K, Manuelyan K. Autoimmune blistering dermatoses as systemic diseases. Clin Dermatol. 2014;32(3):364–75.PubMedCrossRef
191.
Letko E, Gürcan HM, Papaliodis GN, Christen W, Foster CS, Ahmed AR. Relative risk for cancer in mucous membrane pemphigoid associated with antibodies to the beta4 integrin subunit. Clin Exp Dermatol. 2007;32(6):637–41.PubMedCrossRef
192.
Foster ME, Nally FF. Benign mucous membrane pemphigoid (cicatricial mucosal pemphigoid): a reconsideration. Oral Surg Oral Med Oral Pathol. 1977;44(5):697–705.PubMedCrossRef
193.
Frith PA, Venning VA, Wojnarowska F, Millard PR, Bron AJ. Conjunctival involvement in cicatricial and bullous pemphigoid: a clinical and immunopathological study. Br J Ophthalmol. 1989;73(1):52–6.PubMedPubMedCentralCrossRef
194.
Venning VA, Frith PA, Bron AJ, Millard PR, Wojnarowska F. Mucosal involvement in bullous and cicatricial pemphigoid. A clinical and immunopathological study. Br J Dermatol. 1988;118(1):7–15.PubMedCrossRef
195.
Florea F, Koch M, Hashimoto T, Sitaru C. Autoimmunity against laminins. Clin Immunol. 2016;170:39–52.PubMedCrossRef
196.
Matsushima S, Horiguchi Y, Honda T, et al. A case of anti-epiligrin cicatricial pemphigoid associated with lung carcinoma and severe laryngeal stenosis: review of Japanese cases and evaluation of risk for internal malignancy. J Dermatol. 2004;31(1):10–5.PubMedCrossRef
197.
Fleming TE, Korman NJ. Cicatricial pemphigoid. J Am Acad Dermatol. 2000;43(4):571–591 (quiz 591–574).
198.
Shklar G, McCarthy PL. Oral lesions of mucous membrane pemphigoid. A study of 85 cases. Arch Otolaryngol. 1971;93(4):354–64.PubMedCrossRef
199.
Williams DM, Leonard JN, Wright P, et al. Benign mucous membrane (cicatricial) pemphigoid revisited: a clinical and immunological reappraisal. Br Dent J. 1984;157(9):313–6.PubMedCrossRef
200.
201.
Terra JB, Pas HH, Hertl M, Dikkers FG, Kamminga N, Jonkman MF. Immunofluorescence serration pattern analysis as a diagnostic criterion in antilaminin-332 mucous membrane pemphigoid: immunopathological findings and clinical experience in 10 Dutch patients. Br J Dermatol. 2011;165(4):815–22.PubMedCrossRef
202.
Domloge-Hultsch N, Anhalt GJ, Gammon WR, et al. Antiepiligrin cicatricial pemphigoid. A subepithelial bullous disorder. Arch Dermatol. 1994;130(12):1521–9.PubMedCrossRef
203.
Hsu R, Lazarova Z, Yee C, et al. Noncomplement fixing, IgG4 autoantibodies predominate in patients with anti-epiligrin cicatricial pemphigoid. J Invest Dermatol. 1997;109:557–61.PubMedCrossRef
204.
Sadler E, Lazarova Z, Sarasombath P, Yancey KB. A widening perspective regarding the relationship between anti-epiligrin cicatricial pemphigoid and cancer. J Dermatol Sci. 2007;47(1):1–7.PubMedCrossRef
205.
Setterfield J, Shirlaw PJ, Lazarova Z, et al. Paraneoplastic cicatricial pemphigoid. Br J Dermatol. 1999;141(1):127–31.PubMedCrossRef
206.
Bekou V, Thoma-Uszynski S, Wendler O, et al. Detection of laminin 5-specific auto- antibodies in mucous membrane and bullous pemphigoid sera by ELISA. J Invest Dermatol. 2005;124(4):732–40.PubMedCrossRef
207.
Hashimoto T, Dainichi T, Ohyama B, et al. A case of antilaminin 332 mucous membrane pemphigoid showing a blister on the bulbar conjunctiva and a unique epitope on the alpha3 subunit. Br J Dermatol. 2010;162(4):898–9.PubMedCrossRef
208.
Demitsu T, Yoneda K, Iida E, et al. A case of mucous membrane pemphigoid with IgG antibodies against all the alpha3, beta3 and gamma2 subunits of laminin-332 and BP180 C-terminal domain, associated with pancreatic cancer. Clin Exp Dermatol. 2009;34(8):e992–4.PubMedCrossRef
209.
Masunaga K, Toyoda M, Kokuba H, Takahara M, Ohyama B, Hashimoto T, Furue M. Mucous membrane pemphigoid with antibodies to the β3 subunit of laminin 332. J Dermatol. 2011;38(11):1082–4.PubMedCrossRef
210.
Dainichi T, Hirakawa Y, Ishii N, Ohyama B, Kohda F, Takahara M, Moroi Y, Furue M, Yasumoto S, Hashimoto T. Mucous membrane pemphigoid with autoantibodies to all the laminin 332 subunits and fatal outcome resulting from liver cirrhosis and hepatocellular carcinoma. J Am Acad Dermatol. 2011;64(6):1199–200.PubMedCrossRef
211.
Fukuchi O, Suko A, Matsuzaki H, Baba H, Yoshida H, Takeuchi T, Odawara S, Fukuda S, Hashimoto T. Anti-laminin-332 mucous membrane pemphigoid with autoantibodies to α3, β3 and γ2 subunits of laminin-332 as well as to BP230 and periplakin associated with adenocarcinoma from an unknown primary site. J Dermatol. 2013;40(1):61–2.PubMedCrossRef
212.
Hisamatsu Y, Nishiyama T, Amano S, et al. Usefulness of immunoblotting using purified laminin 5 in diagnosis of anti-laminin 5 cicatricial pemphigoid. J Dermatol Sci. 2003;33(2):113–9.PubMedCrossRef
213.
Bhol KC, Dans MJ, Simmons RK, Foster CS, Giancotti FG, Ahmed AR. The autoantibodies to alpha 6 beta 4 integrin of patients affected by ocular cicatricial pemphigoid recognize predominantly epitopes within the large cytoplasmic domain of human beta 4. J Immunol. 2000;165(5):2824–9.PubMedCrossRef
214.
Chan RY, Bhol K, Tesavibul N, et al. The role of antibody to human beta4 integrin in conjunctival basement membrane separation: possible in vitro model for ocular cicatricial pemphigoid. Invest Ophthalmol Vis Sci. 1999;40(10):2283–90.PubMed
215.
Kumari S, Bhol KC, Simmons RK, et al. Identification of ocular cicatricial pemphigoid antibody binding site(s) in human beta4 integrin. Invest Ophthalmol Vis Sci. 2001;42(2):379–85.PubMed
216.
Greer KE, Beacham BE, Askew FC Jr. Benign mucous membrane pemphigoid in association with internal malignancy. Cutis. 1980;25(2):183–5.PubMed
217.
David M, Oren N, Feuerman EJ. Occurrence of cicatricial pemphigoid and leiomyosarcoma in a psoriatic patient. Dermatologica. 1985;170(5):256–9.PubMedCrossRef
218.
Sivalingam V, Shields CL, Shields JA, Pearah JD. Squamous cell carcinoma of the conjunctiva associated with benign mucous membrane pemphigoid. Ann Ophthalmol. 1990;22(3):106–9.PubMed
219.
Hope-Ross M, Benedict-Smith A, Hillery M, Mullaney P, Condon P, Collum LM. Ocular cicatricial pemphigoid and oesophageal carcinoma. Acta Ophthalmol (Copenh). 1990;68(3):361–3.PubMedCrossRef
220.
Ostlere LS, Branfoot AC, Staughton RC. Cicatricial pemphigoid and carcinoma of the pancreas. Clin Exp Dermatol. 1992;17(1):67–8.PubMedCrossRef
221.
Gibson GE, Daoud MS, Pittelkow MR. Anti-epiligrin (laminin 5) cicatricial pemphigoid and lung carcinoma: coincidence or association? Br J Dermatol. 1997;137(5):780–2.PubMedCrossRef
222.
Sabet HY, Davis JL, Rogers RS 3rd. Mucous membrane pemphigoid, thymoma, and myasthenia gravis. Int J Dermatol. 2000;39(9):701–4.PubMedCrossRef
223.
Parisi E, Raghavendra S, Werth VP, Sollecito TP. Modification to the approach of the diagnosis of mucous membrane pemphigoid: a case report and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;95(2):182–6.PubMedCrossRef
224.
Shannon JF, Mackenzie-Wood A, Wood G, Goldstein D. Cicatricial pemphigoid in non-Hodgkin’s lymphoma. Intern Med J. 2003;33(8):396–7.PubMedCrossRef
225.
Seth RK, Su GW, Pflugfelder SC. Mucous membrane pemphigoid in a patient with chronic lymphocytic leukemia. Cornea. 2004;23(7):740–3.PubMedCrossRef
226.
Saravanan K, Baer ST, Meredith A, Dyson A, von der Werth J. Benign mucous membrane pemphigoid of the upper aero-digestive tract: rare paraneoplastic syndrome presentation in renal cell carcinoma. J Laryngol Otol. 2006;120(3):237–9.PubMedCrossRef
227.
Fukushima S, Egawa K, Nishi H, et al. Two cases of anti-epiligrin cicatricial pemphigoid with and without associated malignancy. Acta Derm Venereol. 2008;88(5):484–7.PubMedCrossRef
228.
Takahara M, Tsuji G, Ishii N, et al. Mucous membrane pemphigoid with antibodies to the beta(3) subunit of Laminin 332 in a patient with acute myeloblastic leukemia and graft- versus-host disease. Dermatology. 2009;219(4):361–4.PubMedCrossRef
229.
Egan CA, Lazarova Z, Darling TN, Yee C, Cote T, Yancey KB. Anti-epiligrin cicatricial pemphigoid and relative risk for cancer. Lancet. 2001;357(9271):1850–1.PubMedCrossRef
230.
Young AL, Bailey EE, Colaco SM, Engler DE, Grossman ME. Anti-laminin-332 mucous membrane pemphigoid associated with recurrent metastatic prostate carcinoma: hypothesis for a paraneoplastic phenomenon. Eur J Dermatol. 2011;21(3):401–4.PubMed
231.
Shibuya T, Komatsu S, Takahashi I, Honma M, Takahashi H, Ishida-Yamamoto A, Kamiya T, Fukuda S, Hashimoto T, Iizuka H. Mucous membrane pemphigoid accompanied by ovarian cancer: a case with autoantibodies solely against γ(2)-subunit of laminin-332. J Dermatol. 2012;39(10):882–4.PubMedCrossRef
232.
Ding DC, Chu TY, Hsu YH. Remission of anti-epiligrin cicatricial pemphigoid after excision of cervical adenocarcinoma. J Cutan Pathol. 2014;41(8):692–3.PubMedCrossRef
233.
Shruthy R, Sharada P, Swaminathan U, Nagamalini B. Immunohistochemical expression of basement membrane laminin in histological grades of oral squamous cell carcinoma: a semiquantitative analysis. J Oral Maxillofac Pathol. 2013;17(2):185–9.PubMedPubMedCentralCrossRef
234.
Egan CA, Lazarova Z, Darling TN, Yee C, Yancey KB. Anti-epiligrin cicatricial pemphigoid: clinical findings, immunopathogenesis, and significant associations. Medicine (Baltimore). 2003;82(3):177–86.PubMed
235.
236.
Taniuchi K, Takata M, Matsui C, et al. Antiepiligrin (laminin 5) cicatricial pemphigoid associated with an underlying gastric carcinoma producing laminin 5. Br J Dermatol. 1999;140(4):696–700.PubMedCrossRef
237.
Sami N, Bhol KC, Razzaque Ahmed A. Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid. Clin Immunol. 2002;102(1):59–67.PubMedCrossRef
238.
Uchiyama K, Yamamoto Y, Taniuchi K, Matsui C, Fushida Y, Shirao Y. Remission of antiepiligrin (laminin-5) cicatricial pemphigoid after excision of gastric carcinoma. Cornea. 2000;19(4):564–6.PubMedCrossRef
239.
Kasperkiewicz M, Płatkowska A, Zalewska A, Zillikens D. Heat shock protein 90 inhibition: a potential double- or triple-edged sword in the treatment of mucous membrane pemphigoid. Med Hypotheses. 2015;85(4):412–4.PubMedCrossRef
240.
Allen J, Zhou S, Wakelin SH, Collier PM, Wojnarowska F. Linear IgA disease: a report of two dermal binding sera which recognize a pepsin-sensitive epitope (?NC-1 domain) of collagen type VII. Br J Dermatol. 1997;137(4):526–33.PubMedCrossRef
241.
Caputo R, Bencini PL, Vigo GP, Berti E, Veraldi S. Eruption resembling erythema gyratum repens in linear IgA dermatosis. Dermatology. 1995;190(3):235–7.PubMedCrossRef
242.
Dippel E, Orfanos CE, Zouboulis C. Linear IgA dermatosis presenting with erythema annulare centrifugum lesions: report of three cases in adults. J Eur Acad Dermatol Venereol. 2001;15(2):167–70.PubMedCrossRef
243.
Sato K, Hanazawa H, Sato Y, Watanabe J. Initial presentation and fatal complications of linear IgA bullous dermatosis in the larynx and pharynx. J Laryngol Otol. 2005;119(4):314–8.PubMedCrossRef
244.
Barnadas MA, Moreno A, Brunet S, et al. Linear IgA bullous dermatosis associated with Hodgkin’s disease. J Am Acad Dermatol. 1988;19(6):1122–4.PubMedCrossRef
245.
Godfrey K, Wojnarowska F, Leonard J. Linear IgA disease of adults: association with lymphoproliferative malignancy and possible role of other triggering factors. Br J Dermatol. 1990;123(4):447–52.PubMedCrossRef
246.
247.
Jacyk WK, Nagel GJ, van der Hoven AE. Linear IgA dermatosis and Hodgkin’s lymphoma–report of a case in an African and review of the literature. J Dermatol. 1990;17(10):633–7.PubMedCrossRef
248.
Jones RR, Goolamali SK. IgA bullous pemphigoid: a distinct blistering disorder. Case report and review of the literature. Br J Dermatol. 1980;102(6):719–25.PubMedCrossRef
249.
250.
Keller AS, Bouldin MB, Drage LA, Hauser SC, Davis MD. Linear IgA bullous dermatosis: an association with ulcerative colitis versus renal cell carcinoma. Dig Dis Sci. 2003;48(4):783–9.PubMedCrossRef
251.
Lacour JP, Vitetta A, Ortonne JP. Linear IgA dermatosis and thyroid carcinoma. J Am Acad Dermatol. 1992;26(2 Pt 1):257–9.PubMedCrossRef
252.
Nassar D, Gabillot-Carre M, Ortonne N, et al. Atypical linear IgA dermatosis revealing angioimmunoblastic T-cell lymphoma. Arch Dermatol. 2009;145(3):342–3.PubMedCrossRef
253.
Rodenas JM, Herranz MT, Tercedor J, Concha A. Linear IgA disease in a patient with bladder carcinoma. Br J Dermatol. 1997;136(2):257–9.PubMedCrossRef
254.
Sekula SA, Tschen JA, Bean SF, Wolf JE Jr, Linear IgA bullous disease in a patient with transitional cell carcinoma of the bladder. Cutis. 1986;38(6):354–356, 362.
255.
Usmani N, Baxter KF, Child JA, Sheehan-Dare R. Linear IgA disease in association with chronic lymphocytic leukaemia. Br J Dermatol. 2004;151(3):710–1.PubMedCrossRef
256.
Wojnarowska F, Allen J, Collier P, Whitehead P, Leigh IM. Linear IgA disease: cylindroma demonstrates heterogeneity of the target antigens. Dermatology. 1994;189(Suppl 1):102–4.PubMedCrossRef
257.
Wojnarowska F, Allen J, Collier PM, Leigh IM. A comparison of the expression of known basement membrane components with the linear IgA disease antigens using the novel substrate cylindroma. Br J Dermatol. 1999;141(1):62–70.PubMedCrossRef
258.
Zhou S, Ferguson DJ, Allen J, Wojnarowska F. The localization of target antigens and autoantibodies in linear IgA disease is variable: correlation of immunogold electron microscopy and immunoblotting. Br J Dermatol. 1998;139(4):591–7.PubMedCrossRef
259.
Zone JJ, Taylor TB, Meyer LJ, Petersen MJ. The 97 kDa linear IgA bullous disease antigen is identical to a portion of the extracellular domain of the 180 kDa bullous pemphigoid antigen, BPAg2. J Invest Dermatol. 1998;110(3):207–10.PubMedCrossRef
260.
Ishiko A, Shimizu H, Masunaga T, et al. 97-kDa linear IgA bullous dermatosis (LAD) antigen localizes to the lamina lucida of the epidermal basement membrane. J Invest Dermatol. 1996;106(4):739–43.PubMedCrossRef
261.
McEvoy MT, Connolly SM. Linear IgA dermatosis: association with malignancy. J Am Acad Dermatol. 1990;22(1):59–63.PubMedCrossRef
262.
Lai-Cheong JE, Groves RW, Banerjee P. Linear IgA bullous dermatosis associated with adenocarcinoma of the ascending colon. J Eur Acad Dermatol Venereol. 2007;21(7):978–9.PubMedCrossRef
263.
Tiger JB, Rush JT, Barton DT, Danilov AV, Chapman MS. Urticarial linear IgA bullous dermatosis (LABD) as a presenting sign of chronic lymphocytic leukemia (CLL). JAAD Case Rep. 2015;1(6):412–4.PubMedPubMedCentralCrossRef
264.
Yang CS, Robinson-Bostom L, Landow S. Linear IgA bullous dermatosis associated with metastatic renal cell carcinoma. JAAD Case Rep. 2015;1(2):91–2.PubMedPubMedCentralCrossRef
265.
Kelly SE, Wojnarowska F, Darley C. Linear IgA disease in association with hydatidiform mole. J R Soc Med. 1989;82(7):438–9.PubMedPubMedCentral
266.
Benoit Corven C, Khalaf A, Courville P, Sibert L, Gobet F, Joly P. Renal chromophobe cell carcinoma and paraneoplastic linear IgA bullous dermatosis. J Urol. 2003;169(1):270–1.PubMedCrossRef
267.
Wong DA, Hunt MJ, Stapleton K. IgA multiple myeloma presenting as an acquired bullous disorder. Australas J Dermatol. 1999;40(1):31–4.PubMedCrossRef
268.
Otley CC, Hall RP 3rd. The pathogenesis of dermatitis herpetiformis. Clin Dermatol. 1991;9(3):313–23.PubMedCrossRef
269.
Adamic M, Potocnik M, Pavlovic MD. Linear IgA bullous dermatosis in a patient with advanced pancreatic carcinoma. Clin Exp Dermatol. 2008;33(4):503–5.PubMedCrossRef
270.
Tezuka H, Abe Y, Iwata M, et al. Regulation of IgA production by naturally occurring TNF/iNOS-producing dendritic cells. Nature. 2007;448(7156):929–33.PubMedCrossRef
271.
van der Waal RI, van de Scheur MR, Pas HH, et al. Linear IgA bullous dermatosis in a patient with renal cell carcinoma. Br J Dermatol. 2001;144(4):870–3.PubMedCrossRef
272.
Magyarlaki T, Mosolits S, Baranyay F, Buzogany I. Immunohistochemistry of complement response on human renal cell carcinoma biopsies. Tumori. 1996;82(5):473–9.PubMed
273.
Vissers JL, De Vries IJ, Schreurs MW, et al. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res. 1999;59(21):5554–9.PubMed
274.
Chaffins ML, Collison D, Fivenson DP. Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases. J Am Acad Dermatol. 1993;28(6):998–1000.PubMedCrossRef
Metadaten
Titel
Paraneoplastic Pemphigus and Autoimmune Blistering Diseases Associated with Neoplasm: Characteristics, Diagnosis, Associated Neoplasms, Proposed Pathogenesis, Treatment
verfasst von
Saritha Kartan
Vivian Y. Shi
Ashley K. Clark
Lawrence S. Chan
Publikationsdatum
01.02.2017
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 1/2017
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-016-0235-z

Weitere Artikel der Ausgabe 1/2017

American Journal of Clinical Dermatology 1/2017 Zur Ausgabe

Adis Drug Evaluation

Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis

Review Article

Bathing and Associated Treatments in Atopic Dermatitis

Review Article

Relapsing Polychondritis: A Review and Guide for the Dermatologist

Short Communication

The Utility of Text Message Reminders for Acne Patients: A Pilot Study

Review Article

Laser Tattoo Removal: An Update

Review Article

Literature Review of Cosmetic Procedures in Men: Approaches and Techniques are Gender Specific

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Isotretinoin: Risiko für schwere Laboranomalien „marginal erhöht“

08.05.2024 Akne Nachrichten

Die Aknetherapie mit Isotretinoin kann einen Anstieg von Leberenzymen und Blutfetten verursachen. Das Risiko für schwere Störungen ist laut einer Forschungsgruppe der Universität Lübeck aber nur marginal erhöht und auf einen engen Zeitraum konzentriert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise